A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185

被引：21

作者：

Biagi, J. J.

Oza, A. M.

Grimshaw, R.

Ellard, S. L.

Lee, U.

Sederias, J.

Ivy, S. P.

Eisenhauer, E. A.

机构：

[1] Canc Ctr SE Ontario, Kingston, ON, Canada

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[4] British Columbia Canc Ctr So Interior, Kelowna, BC, Canada

[5] Fraser Valley Ctr, British Columbia Canc Ctr, Surrey, BC, Canada

[6] NCIC Clin Trials Grp, Kingston, ON, Canada

[7] NCI, Therapy Evaluat Program, Bethesda, MD 20892 USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.5522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5522

引用

页数：1